Anticoagulation with oral vitamin-K-antagonists in risk patients: Clinical and economical benefit of an adequate prevention;Antikoagulation mit oralen vitamin-K-antagonisten bei risikopatienten: Klinischer und wirtschaftlicher nutzen einer adäquaten prävention

Journal fur Kardiologie

Volumn 13, Issue 9-10, 2006, Pages 313-320

  Neeser, Kurt ^a   Erny Albrecht, K ^a   Voller H ^b   Weber, C ^a  

^a Institut für Medizininformatik und Biostatistik IMIB   (Switzerland)

^b Klinik am See   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; WARFARIN;

AMBULATORY MONITORING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; MORTALITY; OVERALL SURVIVAL; RISK FACTOR; SCORING SYSTEM; SELF MONITORING; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33750054996     PISSN: 10240098     EISSN: 1680936X     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
2. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
3. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-8.
4. Osterkamp R. Bevölkerungsentwicklung in Deutschland bis 2050. Chirurg 2005; 76: 10-8.
5. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90: 286-92.
6. Matchar DB, Jacobson AK, Edson RG, Lavori PW, Ansell JE, Ezekowitz MD, Rickles F, Fiore L, Boardman K, Phibbs C, Fihn SD, Vertrees JE, Dolor R. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481 - the Home INR Study (THINRS). J Thromb Thrombolysis 2005; 19: 163-72.
7. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000; 2: CD001927.
8. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-8.
9. Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ 1999; 161: 493-7.
10. McCahon D, Fitzmaurice DA, Murray ET, Fuller CJ, Hobbs RF, Allan TF, Raftery JP. SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]. BMC Fam Pract 2003; 4: 11.
11. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl 1): 8S-21S.
12. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-6.
13. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse outcomes and predictors of under-use of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-7.
14. Gohlke-Barwolf C, Acar J, Oakley C, Butchart E, Burckhart D, Bodnar E, Hall R, Delahaye JP, Horstkotte D, Kremer R. Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 1995; 16: 1320-30.
15. Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98: 1949-84.
16. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. ACC/AHA Guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Heart Valve Dis 1998; 7: 672-707.
17. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 1999; 245: 369-74.
18. Müller E, Bergemann R. Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7). Eur Heart J 2001; 3 (Suppl Q): Q65-Q69.
19. Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987; 44: 430-45.
20. Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001; 72: 44-8.
21. Koertke H, Minami K, Bairaktaris A, Wagner O, Koerfer R. INR self-management following mechanical heart valve replacement. J Thromb Thrombolysis 2000; 9 (Suppl 1): S41-S45.
22. Preiss M, Bernet F, Zerkowski H. Additional information from the GELIA database: analysis of benefit from self management of oral anticoagulation (GELIA 6). Eur Heart J 2001; 3 (Suppl Q): Q50-Q53.
23. Tretjak I, Benvenuto G, Drigo F, Casson M, Barocchi G, Humar F, Pivotti F, Fisicaro M, Giansante C, Scardi S. [Control of anticoagulant therapy with portable prothrombin time device in patients with mechanical heart valve prostheses: two-year follow-up]. Monaldi Arch Chest Dis 2003; 60: 288-94.
24. Caliezi C, Niederer A, Wuillemin WA. [Patient self-management of oral anticoagulation]. Ther Umsch 2003; 60: 59-62.
25. Gohlke-Barwolf C. [Current recommendations for prevention of thromboembolism in patients with heart valve prostheses]. Z Kardiol 2001; 90 (Suppl 6): 112-7.
26. Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001; 72: 1523-7.
27. Gold MR, Siegel JE, Russel L, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press, New York, 1996.
28. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8: iii-xi, 1.
29. Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, Barbieri M. Use of pharmacoeconomics information - report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003; 6: 407-16.
30. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
31. Gage BF, Van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-92.
32. Rote Liste (online access). ECV Editis Cantor Verlag, Aulendorf/Württemberg, 2005.
33. Köhler A, Hess R. Kölner Kommentar zum EBM. 2. Aufl. Deutscher Ärzte-Verlag, Köln, 2002.
34. Online Apotheke: Bienen-Apotheke Angela Maier und Michael Grintz OHG. www.apobee.de. Access date November 2005.
35. Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 2003; 15: 29-36.
36. Laaser U, Breckenkamp J, Niermann U. Cost-effectiveness-analysis of medical interventions in patients with stroke in Germany under special consideration of "stroke units". Gesundh ökon Qual manag 1999; 4: 176-83.
37. Vollmer RJ, Vollmer PM. Handbuch der Vorsorge- und Rehabilitations- Einrichtungen in der Bundesrepublik Deutschland. AOK-Verlag, Remagen, 1999.
38. Ringelstein EB. Empfehlungen für die Einrichtung von Schlaganfallspezialstationen ("Stroke Units"). Aktualisierung 1997. Nervenarzt 1998; 69: 180-5.
39. Krankenhausdiagnosestatistik. Diagnosedaten der Krankenhauspatienten 1997. Statistisches Bundesamt, Wiesbaden, 1999.
40. Stationäre Gesundheitsversorgung. Gesundheitsbericht für Deutschland. Statistisches Bundesamt, Wiesbaden, 1998; 410-3.
41. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomic Guidelines Around the World: Germany. Country-specific pharmacoeconomic guidelines 2005. 4.10.2005.
42. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
43. Desai M. NDA 21-686 Ximelagatran (H376/95). FDA preliminary report. FDA, Rockville, 2004; 1-33.
44. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-11.
45. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
46. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
47. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
48. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
49. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4: 348-61.
50. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90.
51. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685-92.
52. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138: 831-8.
53. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2004; 2: CD000185.
54. Aguilar M, Hart R. Oral anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005; 3: CD001927.
55. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 429S-456S.
56. Koertke H, Minami K, Boethig D, Breymann T, Seifert D, Wagner O, Atmacha N, Krian A, Ennker J, Taborski U, Klovekorn WP, Moosdorf R, Saggau W, Koerfer R. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003; 108 (Suppl 1): II75-II78.
57. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost 1999; 25: 103-7.
58. Lafata JE, Martin SA, Kaatz S, Ward RE. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. J Thromb Thrombolysis 2000; 9 (Suppl 1): S13-S19.